FDA Approves Ixifi (infliximab-qbtx), a Biosimilar to Remicade

December 13, 2017 -- Pfizer Inc. (NYSE:PFE) announced today that the United States (U.S.) Food and Drug Administration (FDA) has approved Ixifi (PF-06438179, infliximab-qbtx), a chimeric human-murine monoclonal antibody (mAb) against tumor...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news